2020
DOI: 10.1016/j.jaad.2018.02.021
|View full text |Cite
|
Sign up to set email alerts
|

Diagnosis and management of pemphigus: Recommendations of an international panel of experts

Abstract: We present here the recommendations resulting from this Delphi process. This international consensus includes intravenous CD20 inhibitors as a first line therapy option for moderate to severe pemphigus.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

2
303
2
18

Year Published

2021
2021
2023
2023

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 247 publications
(325 citation statements)
references
References 10 publications
2
303
2
18
Order By: Relevance
“…In our study, we evaluated the efficacy of methylprednisolone Murrell et al, 2018). In our study, rituximab prescription has been increased progressively from 16% in early years of study in patients with severe life-threatening disease and resistant to pulse therapy plus other adjuvant drugs especially, to about 35% in the last year of the study, even it was the first choice of adjuvant therapy, but not as monotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…In our study, we evaluated the efficacy of methylprednisolone Murrell et al, 2018). In our study, rituximab prescription has been increased progressively from 16% in early years of study in patients with severe life-threatening disease and resistant to pulse therapy plus other adjuvant drugs especially, to about 35% in the last year of the study, even it was the first choice of adjuvant therapy, but not as monotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…Several reports have demonstrated that rituximab therapy is effective for severe and refractory pemphigus (Ahmed & Shetty, ; Joly et al, ). Recent articles recommend rituximab for pemphigus, although relapse is common (Murrell et al, ). Thus, we investigated the clinical risk factors for poor clinical outcomes and relapse in pemphigus.…”
Section: Introductionmentioning
confidence: 99%
“…It should be noted that also cyclophosmamide, another common therapeutic option for pemphigus, has been associated with an increased risk of malignancies (Bernatsky et al, 2014). These considerations support the use of RTX as first-line therapy for moderate-to-severe pemphigus, as recommended by a recent consensus statement (Murrell et al, 2018), since its use has not been associated with a malignancy risk (van Daalen et al, 2017).…”
Section: Discussionmentioning
confidence: 89%